Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 15;127(6):976-978.
doi: 10.1002/cncr.33281. Epub 2020 Oct 23.

Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study

Emilie Cayssials  1   2   3 , Jose Torregrosa-Diaz  1   2 , Xavier Leleu  1   2 , François Guilhot  2 , Jean-Claude Chomel  4
Affiliations
Free article
Comment

Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study

Emilie Cayssials et al. Cancer. .
Free article
No abstract available

PubMed Disclaimer

Comment on

References

    1. Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, et al. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: results of a retrospective study. Cancer. 2020;126:3438-3447.
    1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
    1. Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67-75.
    1. Eadie LN, Hughes TP, White DL. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia. 2018;32:2288-2291.
    1. Bouchet S, Rousselot P, Guilhot F, et al. Dasatinib daily dose optimization based on therapeutic drug monitoring resulted in reduced risk of pleural effusions and high molecular response rates. Fundam Clin Pharmacol. 2015;29:9-10.

MeSH terms

Substances

LinkOut - more resources